N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome

Overview

We would study whether there is any measurable benefit of the administration of nebulized n-acetyl-cysteine to acute respiratory distress syndrome patients starting within 48 hours of intubation and mechanical ventilation.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 30, 2021

Detailed Description

Objectives / Research Aims The overall objectives of this study are to demonstrate whether a protocol for the early use of inhaled N-acetylcysteine improves mortality, ventilator days, ICU days, hospital stay, as well as the need for other "rescue" modalities, such as use of advanced ventilator modalities (such as airway pressure release ventilation [APRV]), paralytics, and prone positioning. As this is a pilot study, we would address the feasibility of recruiting and consenting patients as well as to ascertain the sample size that would be needed to power the desired endpoints in a larger study. Setting The project will be performed in the Medical Intensive Care Unit at Palmetto Health Richland using subjects with severe acute respiratory distress syndrome that are identified within 48 hours of their disease process. Resources Available It is not uncommon for the patients admitted with or that develop acute respiratory distress syndrome to receive breathing treatments of some variety, such as bronchodilators. This study would take an existing practice and add a relatively inexpensive medication, N-acetylcysteine. It will be straightforward and require relatively little time to calculate the metrics for the patients enrolled in this study as these data are typically collected for intensive care unit patients already. Our respiratory therapists are already very experienced and proficient at the administration of inhaled N-acetylcysteine. Likewise, the academic intensive care team would be able to readily classify the patients that are appropriate for this study as the partial pressure of oxygen to fraction of inspired oxygen (P/F) ratio is typically documented for every ventilated patient admitted to our unit. Study Design Recruitment Methods The patients will be recruited based upon their P/F ratio less than 150 and being mechanically ventilated with a positive end expiratory pressure of 5 or greater. These patients will be started on the protocol within 48 hours of developing acute respiratory distress syndrome. Inclusion and Exclusion Criteria Inclusion criteria includes adult patients admitted to the medical intensive care unit or coronary care unit, being mechanically ventilated with a positive end expiratory pressure greater than 5 cm H2O, with noncardiogenic pulmonary edema on chest x-ray within 48 hours of being noted to have a P/F ratio < 150. Exclusion criteria includes patients < 18 years of age, patients for whom no aggressive measures are desired, patients who are already receiving "rescue methods" (prone positioning, advanced ventilator modes, paralytics), trauma patients, vulnerable patient groups (pregnant, prisoners), patients who have undergone a surgical operation during their time on the ventilator, patients with end stage liver disease, patients on chronic ventilators, and asthmatics. Local Number of Subjects This study will seek to enroll 26 patients each in the treatment and control arm. Study-Wide Number of Subjects This is a single center study. Study Timelines Plans will be to complete the study within 12 months from the time of start. Study Endpoints The patient is liberated from the ventilator, discharged from the ICU, discharged from the hospital, or dies. Procedures Involved The only procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 3 2 mL 20% solution acetylcysteine (or 6 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.). The patients would be monitored daily in the ICU setting with lab work, including arterial blood gases, chemistry panels, complete blood counts. They would have all routine critical care monitoring, such as hourly vital signs, urine output, ventilation parameters in accordance with the nature of their critical illness.

Interventions

  • Drug: N-acetyl cysteine
    • The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).

Arms, Groups and Cohorts

  • Experimental: NAC and albuterol
    • The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
  • No Intervention: Albuterol
    • Albuterol will be administered via nebulization every six hours.

Clinical Trial Outcome Measures

Primary Measures

  • Ventilator days
    • Time Frame: From time of intubation until one of predefined endpoints (up to 60 days)
    • Number of days requiring mechanical ventilation

Secondary Measures

  • Mortality
    • Time Frame: up to 60 days
    • Number of days until expiring
  • ICU days
    • Time Frame: From time of admission to the ICU until transfer out of the unit (up to 60 days)
    • Number of days in the ICU
  • P/F ratio
    • Time Frame: Daily until the predefined endpoints (up to 60 days)
    • A measure of the partial pressure of oxygen divided by the percentage of inhaled oxygen
  • Use of “rescue” maneuvers
    • Time Frame: Daily until the predefined endpoints (up to 60 days)
    • Using airway pressure release ventilation, paralytics, or proning

Participating in This Clinical Trial

Inclusion Criteria

Inclusion criteria includes adult patients admitted to the medical intensive care unit or coronary care unit, being mechanically ventilated with a positive end expiratory pressure greater than 5 cm H2O, with noncardiogenic pulmonary edema on chest x-ray within 48 hours of being noted to have a P/F ratio < 150. Exclusion Criteria:

Exclusion criteria includes patients < 18 years of age, patients for whom no aggressive measures are desired, patients who are already receiving "rescue methods" (prone positioning, advanced ventilator modes, paralytics), trauma patients, vulnerable patient groups (pregnant, prisoners), patients who have undergone a surgical operation during their time on the ventilator, patients with end stage liver disease, patients on chronic ventilators, and asthmatics.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Prisma Health-Midlands
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Judson Lewis, MD, Principal Investigator, Prisma Health-Midlands

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.